Thiakis - home page

Latest News
Archive

12 March 2008

Novel therapy for treatment of obesity enters clinical trials

Thiakis announces that it has commenced dosing in a clinical trial of TKS1225, a novel oxyntomodulin analogue for the treatment of obesity.

Full Press Release

21 August 2006

Thiakis Receives £10 Million Investment For Development Of Obesity Therapy

Thiakis Limited, a UK based biopharmaceutical company focused on the development of peptide hormones for the treatment of obesity, announces it has completed a £10 million ($19 million) Series A financing round. The investment syndicate was jointly led by Novo A/S and Advent Venture Partners, both leading international life science venture capital groups. Martin Edwards of Novo A/S and Raj Parekh of Advent Venture Partners will join the Board of Thiakis.

Full Press Release

18 August 2006

Thiakis Moves Into Imperial BioIncubator

Thiakis Limited announces it has become one of the first tenants of the newly-opened Imperial BioIncubator, located on Imperial College London’s South Kensington campus.

Full Press Release

5 May 2006

Thiakis gains rights to novel peptides for the treatment of obesity

Thiakis and Imperial Innovations Ltd, the technology commercialisation company based at Imperial College London, announce the signing of exclusive licence and option agreements for novel oxyntomodulin analogues for the treatment of obesity. Under the agreements, Imperial Innovations is entitled to receive an upfront payment, further payments based on the achievement of development milestones, and royalties on sales of oxyntomodulin analogues for the treatment of obesity.

Full Press Release